CS
ROIV icon

Candriam SCA’s Roivant Sciences ROIV Stock Holding History

Candriam SCA’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.4M Sell
1,990,510
-11,466
-0.6% -$339K 0.32% 65
2026
Q1 		$55.5M Sell
2,001,976
-488,450
-20% -$12.5M 0.29% 78
2025
Q4 		$54M Buy
2,490,426
+332,431
+15% +$6.56M 0.27% 86
2025
Q3 		$32.7M Buy
2,157,995
+654,001
+43% +$8.1M 0.17% 125
2025
Q2 		$17M Buy
1,503,994
+1,476,646
+5,399% +$16M 0.1% 191
2025
Q1 		$276K Buy
+27,348
New +$296K ﹤0.01% 657

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Candriam SCA's ROIV Position: Q2 2026 in Review

Candriam SCA reduced its Roivant Sciences (ROIV) stake by 0.57% in Q2 2026, selling an estimated $339K and leaving 1,990,510 shares worth $70.4M. The position accounts for 0.32% of the portfolio, ranked #65.

Candriam SCA first reported a position in ROIV in Q1 2025 and has held it in 6 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Candriam SCA held 1,990,510 shares of Roivant Sciences worth $70.4M as of Q2 2026.
  • Candriam SCA sold 11,466 Roivant Sciences shares in Q2 2026, an estimated $339K.
  • Roivant Sciences made up 0.32% of Candriam SCA's portfolio in Q2 2026, its #65 holding.
  • Candriam SCA first reported a position in Roivant Sciences in Q1 2025 and has held it in 6 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.